{
  "id": "mhgap#screening_cues_8a1b73d2",
  "title_en": "General — Screening Cues",
  "title_vi": "General — Dấu hiệu sàng lọc",
  "text_en": "lowest effective dose. keeping in mind the wishes of the person with dementia. If appropriate: – Monitor the person for extrapyramidal symptoms (EPS) Provide training and support in specific skills, e.g. F or dementia with suspected Alzhemer’s Disease, Avoid i.v. haloperidol managing difficult behaviour, if necessary. To be most and with CLOSE MONITORING, consider cholinesterase effective, elicit active participation, e.g. role play. inhibitors (e.g. donepezil, galantamine, rivastigmine) Avoid diazepam. OR memantine. Consider providing practical support when feasible, e.g. home-based respite care. Another family or suitable F or dementia with associated vascular disease, consider person can supervise and care for the person with memantine. dementia to provide the main carer with a period of relief to rest or carry out other activities. Explore whether the person qualifies for any disability benefits or other social/financial support (government or non-governmental). DEM 3 Follow-up RECOMMENDATIONS ON FREQUENCY OF CONTACT 1 » Follow-up at minimum every 3 months. » ASSESS FOR IMPROVEMENT If on medications, recommend follow-up monthly. Is the person stable (no worsening symptoms or decline in function; behavioural/psychological symptoms are improving if present)? Continue management plan. If not on medications Initiate pharmacological intervention, if appropriate. Follow up at minimum every 3 months. If on medications Review adherence, side effects and dosing. Adjust or consider alternative medication as appropriate. Review psychosocial interventions. Evaluate for medical problems. DEMENTIA 103",
  "gloss_vi": "Lowest effective dose. keeping in mind the wishes of the person with dementia.",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "screening_cues",
      "referral",
      "psychoeducation",
      "do_not_do",
      "management",
      "caregiver"
    ],
    "life_topics": [
      "relationships"
    ],
    "advice_section": [
      "work_habits"
    ],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Screening Cues General — Dấu hiệu sàng lọc lowest effective dose. keeping in mind the wishes of the person with dementia. If appropriate: – Monitor the person for extrapyramidal symptoms (EPS) Provide training and support in specific skills, e.g. F or dementia with suspected Alzhemer’s Disease, Avoid i.v. haloperidol managing difficult behaviour, if necessary. To be most and with CLOSE MONITORING, consider cholinesterase effective, elicit active participation, e.g. role play. inhibitors (e.g. donepezil, galantamine, rivastigmine) Avoid diazepam. OR memantine. Consider providing practical support when feasible, e.g. home-based respite care. Another family or suitable F or dementia with associated vascular disease, consider person can supervise and care for the person with memantine. dementia to provide the main carer with a period of relief to rest or carry out other activities. Explore whether the person qualifies for any disability benefits or other social/financial support (government or non-governmental). DEM 3 Follow-up RECOMMENDATIONS ON FREQUENCY OF CONTACT 1 » Follow-up at minimum every 3 months. » ASSESS FOR IMPROVEMENT If on medications, recommend follow-up monthly. Is the person stable (no worsening symptoms or decline in function; behavioural/psychological symptoms are improving if present)? Continue management plan. If not on medications Initiate pharmacological intervention, if appropriate. Follow up at minimum every 3 months. If on medications Review adherence, side effects and dosing. Adjust or consider alternative medication as appropriate. Review psychosocial interventions. Evaluate for medical problems. DEMENTIA 103 Lowest effective dose. keeping in mind the wishes of the person with dementia."
}